CA2934612C - Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition - Google Patents

Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition Download PDF

Info

Publication number
CA2934612C
CA2934612C CA2934612A CA2934612A CA2934612C CA 2934612 C CA2934612 C CA 2934612C CA 2934612 A CA2934612 A CA 2934612A CA 2934612 A CA2934612 A CA 2934612A CA 2934612 C CA2934612 C CA 2934612C
Authority
CA
Canada
Prior art keywords
castor oil
pharmaceutical composition
pyridin
acceptable salt
pharmaceutically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2934612A
Other languages
English (en)
French (fr)
Other versions
CA2934612A1 (en
Inventor
Yoko Endo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of CA2934612A1 publication Critical patent/CA2934612A1/en
Application granted granted Critical
Publication of CA2934612C publication Critical patent/CA2934612C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2934612A 2014-01-10 2015-01-08 Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition Active CA2934612C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014002809 2014-01-10
JP2014-002809 2014-01-10
PCT/JP2015/050333 WO2015105134A1 (ja) 2014-01-10 2015-01-08 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物

Publications (2)

Publication Number Publication Date
CA2934612A1 CA2934612A1 (en) 2015-07-16
CA2934612C true CA2934612C (en) 2021-09-07

Family

ID=53523959

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2934612A Active CA2934612C (en) 2014-01-10 2015-01-08 Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition

Country Status (19)

Country Link
US (3) US20160317512A1 (cg-RX-API-DMAC7.html)
EP (2) EP3093021B1 (cg-RX-API-DMAC7.html)
JP (5) JP6012775B2 (cg-RX-API-DMAC7.html)
KR (6) KR102111157B1 (cg-RX-API-DMAC7.html)
CN (2) CN110251516B (cg-RX-API-DMAC7.html)
AU (1) AU2015205268B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016015911B1 (cg-RX-API-DMAC7.html)
CA (1) CA2934612C (cg-RX-API-DMAC7.html)
EA (1) EA031723B1 (cg-RX-API-DMAC7.html)
ES (2) ES2953346T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20186916B (cg-RX-API-DMAC7.html)
IL (1) IL246654B (cg-RX-API-DMAC7.html)
MX (1) MX2016009058A (cg-RX-API-DMAC7.html)
MY (1) MY166210A (cg-RX-API-DMAC7.html)
PH (1) PH12016501327A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201605532YA (cg-RX-API-DMAC7.html)
TW (1) TWI612960B (cg-RX-API-DMAC7.html)
UA (1) UA121744C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015105134A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102111157B1 (ko) * 2014-01-10 2020-05-14 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
MX385505B (es) 2014-01-10 2025-03-18 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico
KR101824829B1 (ko) 2014-01-10 2018-02-01 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물을 포함하는 의약 제제
TWI794140B (zh) 2015-07-09 2023-03-01 日商參天製藥股份有限公司 含有吡啶基胺基乙酸化合物之預防及/或治療劑
EP3639854B1 (en) 2017-06-16 2026-01-07 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy
WO2018230713A1 (ja) 2017-06-16 2018-12-20 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
EP3689349A4 (en) * 2017-09-29 2021-06-23 Santen Pharmaceutical Co., Ltd. MEDICINAL PRODUCT CONTAINING A COMPOUND OF PYRIDYLAMINOACETIC ACID
KR20200103041A (ko) 2017-12-21 2020-09-01 산텐 세이야꾸 가부시키가이샤 오미데네팍의 조합
US11666563B2 (en) * 2017-12-28 2023-06-06 Santen Pharmaceutical Co., Ltd. Pharmaceutical preparation containing pyridyl aminoacetic acid compound
CN114761022B (zh) * 2019-11-29 2024-02-13 千寿制药株式会社 药物组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
JP3297969B2 (ja) * 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
EP0938896A1 (en) 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
CA2295512C (en) * 1998-07-14 2009-05-26 Alcon Laboratories, Inc. Prostaglandin product
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US20020009507A1 (en) * 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
JP5460996B2 (ja) 2007-10-19 2014-04-02 大正製薬株式会社 眼科用剤
HRP20190509T1 (hr) * 2008-03-12 2019-05-03 Ube Industries, Ltd. Spoj piridilaminooctene kiseline
PT2415763E (pt) 2009-03-30 2016-03-30 Ube Industries Composição farmacêutica para tratamento ou prevenção do glaucoma
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
TW201309343A (zh) 2011-02-10 2013-03-01 參天製藥股份有限公司 經改善親水性藥物之藥物移行性之水性組成物
CN103596572A (zh) 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
TW201340960A (zh) 2012-02-27 2013-10-16 Rohto Pharma 眼科用組成物套組
MY169816A (en) 2012-03-26 2019-05-16 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
CN104428911B (zh) 2012-07-09 2018-08-24 夏普株式会社 发光装置以及照明装置
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
US20140018350A1 (en) * 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
KR102074020B1 (ko) 2012-07-13 2020-02-05 산텐 세이야꾸 가부시키가이샤 술폰아미드 화합물의 조합
KR102111157B1 (ko) 2014-01-10 2020-05-14 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
MX385505B (es) 2014-01-10 2025-03-18 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico
KR101824829B1 (ko) * 2014-01-10 2018-02-01 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물을 포함하는 의약 제제
EP3689349A4 (en) 2017-09-29 2021-06-23 Santen Pharmaceutical Co., Ltd. MEDICINAL PRODUCT CONTAINING A COMPOUND OF PYRIDYLAMINOACETIC ACID

Also Published As

Publication number Publication date
KR102458180B1 (ko) 2022-10-21
GEP20186916B (en) 2018-11-12
US20230372316A1 (en) 2023-11-23
KR102230683B1 (ko) 2021-03-19
EA201691139A1 (ru) 2017-02-28
JP2019034973A (ja) 2019-03-07
US20160317512A1 (en) 2016-11-03
EP3888654A1 (en) 2021-10-06
IL246654A0 (en) 2016-08-31
JP7546027B2 (ja) 2024-09-05
WO2015105134A1 (ja) 2015-07-16
JP2022189964A (ja) 2022-12-22
PH12016501327B1 (en) 2017-02-06
BR112016015911A2 (cg-RX-API-DMAC7.html) 2017-08-08
UA121744C2 (uk) 2020-07-27
JP2021011508A (ja) 2021-02-04
KR20160100977A (ko) 2016-08-24
EP3093021B1 (en) 2021-06-02
MX2016009058A (es) 2016-09-09
HK1224191A1 (zh) 2017-08-18
KR102675685B1 (ko) 2024-06-14
CN110251516A (zh) 2019-09-20
CA2934612A1 (en) 2015-07-16
CN105828817A (zh) 2016-08-03
BR112016015911B1 (pt) 2022-04-05
KR20180050770A (ko) 2018-05-15
JP2017031177A (ja) 2017-02-09
SG11201605532YA (en) 2016-08-30
EP3093021A1 (en) 2016-11-16
JP6449205B2 (ja) 2019-01-09
KR20210032547A (ko) 2021-03-24
KR20220146691A (ko) 2022-11-01
JP6012775B2 (ja) 2016-10-25
ES2953346T3 (es) 2023-11-10
IL246654B (en) 2020-05-31
JP7170020B2 (ja) 2022-11-11
JP6793172B2 (ja) 2020-12-02
KR101858373B1 (ko) 2018-05-15
KR102984133B1 (ko) 2026-06-29
TW201611833A (en) 2016-04-01
US20200113880A1 (en) 2020-04-16
JP2015147762A (ja) 2015-08-20
KR20240096869A (ko) 2024-06-26
KR102111157B1 (ko) 2020-05-14
US12678429B2 (en) 2026-07-14
EA031723B1 (ru) 2019-02-28
MY166210A (en) 2018-06-22
CN105828817B (zh) 2019-07-05
TWI612960B (zh) 2018-02-01
AU2015205268B2 (en) 2019-03-14
NZ721530A (en) 2021-03-26
CN110251516B (zh) 2022-05-03
EP3093021A4 (en) 2017-07-26
ES2874547T3 (es) 2021-11-05
EP3888654B1 (en) 2023-06-14
KR20200053651A (ko) 2020-05-18
AU2015205268A1 (en) 2016-07-14
GEAP201814216A (en) 2018-07-25
PH12016501327A1 (en) 2017-02-06

Similar Documents

Publication Publication Date Title
AU2015205268B2 (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
US10149908B2 (en) Pharmaceutical composition containing pyridylaminoacetic acid compound
NZ721530B2 (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
HK1227322B (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
HK1227322A1 (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
HK1224191B (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191017

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241204

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241204

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241204

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251202